Abstract
Four years ago, the federal Food and Drug Administration (FDA) awarded eight companies “Innovation Challenge” grants to spur the development of medical devices that would prevent and treat opioid use disorder (OUD) (see https://onlinelibrary.wiley.com/doi/10.1002/adaw.32191). This month, the FDA cleared the Masimo Opioid Halo — the first winner of the challenge — for over‐the‐counter availability for use on adults and children aged 15 and older, and a prescription version for use from a health care provider.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
